PMID- 37431919
OWN - NLM
STAT- MEDLINE
DCOM- 20231026
LR  - 20231026
IS  - 1098-2744 (Electronic)
IS  - 0899-1987 (Linking)
VI  - 62
IP  - 11
DP  - 2023 Nov
TI  - Circ_0001589/miR-1248/HMGB1 axis enhances EMT-mediated metastasis and cisplatin 
      resistance in cervical cancer.
PG  - 1645-1658
LID - 10.1002/mc.23605 [doi]
AB  - Cervical cancer is the fourth most common malignant tumors in female worldwide. 
      Cirular RNAs (circRNA) represent a new class of regulatory RNA and play a pivotal 
      role in the carcinogenesis and development of tumors. However, their functions 
      have not been fully elucidated in cervical cancer. In this study, we identified 
      an upregulated circRNA, circ_0001589, both in fresh clinical samples and tissue 
      microarray of cervical cancer. Transwell assay and cell apoptosis assay by flow 
      cytometry demonstrated circ_0001589 promotes epithelial-mesenchymal transition 
      (EMT)-mediated cell migration and invasion, and enhanced cisplatin resistance in 
      vitro. In addition, in nude mice model, circ_0001589 increased the number of lung 
      metastases and recovered xenograft growth from cisplatin treatment in vivo. 
      Mechanistically, RNA pull-down assay, RNA immunoprecipitation, and 
      dual-luciferase reporter assay disclosed that circ_0001589 function as an 
      competing endogenous RNA to sponge miR-1248, which directly target the 3' 
      untranslated region of high mobility group box-B1 (HMGB1). Thereby, circ_0001589 
      upregulated HMGB1 protein expression and accelerate cervical cancer progression. 
      The rescue experiments also revealed that miR-1248 overexpression or HMGB1 
      knockdown partially reversed the regulatory functions of circ_0001589 on cell 
      migration, invasion, and cisplatin resistance. In summary, our findings suggest 
      the upregulation of circ_0001589 promoted EMT-mediated cell migration and 
      invasion, and enhanced cisplatin resistance via regulating miR-1248/HMGB1 axis in 
      cervical cancer. These results provided new evidence for understanding the 
      carcinogenesis mechanism and finding new therapeutic target for cervical cancer.
CI  - (c) 2023 Wiley Periodicals LLC.
FAU - Ma, Teng
AU  - Ma T
AD  - Department of Obstetrics and Gynecology, Daping Hospital, Army Medical University 
      (Third Military Medical University), Chongqing, China.
FAU - Guo, Jianxin
AU  - Guo J
AD  - Department of Obstetrics and Gynecology, Daping Hospital, Army Medical University 
      (Third Military Medical University), Chongqing, China.
FAU - Han, Jian
AU  - Han J
AD  - Department of Obstetrics and Gynecology, Daping Hospital, Army Medical University 
      (Third Military Medical University), Chongqing, China.
FAU - Li, Lanfang
AU  - Li L
AD  - Department of Obstetrics and Gynecology, Daping Hospital, Army Medical University 
      (Third Military Medical University), Chongqing, China.
FAU - Ren, Yifei
AU  - Ren Y
AD  - Department of Obstetrics and Gynecology, Daping Hospital, Army Medical University 
      (Third Military Medical University), Chongqing, China.
FAU - Huang, Jie
AU  - Huang J
AD  - Department of Obstetrics and Gynecology, Daping Hospital, Army Medical University 
      (Third Military Medical University), Chongqing, China.
FAU - Diao, Ge
AU  - Diao G
AD  - Department of Obstetrics and Gynecology, Daping Hospital, Army Medical University 
      (Third Military Medical University), Chongqing, China.
FAU - Zheng, Xiuhui
AU  - Zheng X
AD  - Department of Obstetrics and Gynecology, Daping Hospital, Army Medical University 
      (Third Military Medical University), Chongqing, China.
FAU - Zheng, Yingru
AU  - Zheng Y
AUID- ORCID: 0000-0002-4146-7796
AD  - Department of Obstetrics and Gynecology, Daping Hospital, Army Medical University 
      (Third Military Medical University), Chongqing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230711
PL  - United States
TA  - Mol Carcinog
JT  - Molecular carcinogenesis
JID - 8811105
RN  - 0 (3' Untranslated Regions)
RN  - Q20Q21Q62J (Cisplatin)
RN  - 0 (HMGB1 Protein)
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Circular)
RN  - 0 (HMGB1 protein, human)
SB  - IM
MH  - Animals
MH  - Female
MH  - Humans
MH  - Mice
MH  - 3' Untranslated Regions
MH  - Carcinogenesis
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Cisplatin/pharmacology
MH  - Epithelial-Mesenchymal Transition
MH  - *HMGB1 Protein
MH  - Mice, Nude
MH  - *MicroRNAs/genetics
MH  - *Rectal Neoplasms
MH  - RNA, Circular/genetics
MH  - *Uterine Cervical Neoplasms/drug therapy/genetics
OTO - NOTNLM
OT  - cervical cancer
OT  - circular RNA
OT  - drug resistance
OT  - metastasis
EDAT- 2023/07/11 13:10
MHDA- 2023/10/23 00:43
CRDT- 2023/07/11 08:03
PHST- 2023/05/30 00:00 [revised]
PHST- 2023/03/23 00:00 [received]
PHST- 2023/06/11 00:00 [accepted]
PHST- 2023/10/23 00:43 [medline]
PHST- 2023/07/11 13:10 [pubmed]
PHST- 2023/07/11 08:03 [entrez]
AID - 10.1002/mc.23605 [doi]
PST - ppublish
SO  - Mol Carcinog. 2023 Nov;62(11):1645-1658. doi: 10.1002/mc.23605. Epub 2023 Jul 11.